dc.contributor.author
Andrés Benito, Pol
dc.contributor.author
Povedano, Mònica
dc.contributor.author
Domínguez, Raúl
dc.contributor.author
Marco, Carla
dc.contributor.author
Colomina Soler, M. J. (María José)
dc.contributor.author
López Pérez, Óscar
dc.contributor.author
Santana, Isabel
dc.contributor.author
Baldeiras, Inês
dc.contributor.author
Martínez Yélamos, Sergio
dc.contributor.author
Zerr, Inga
dc.contributor.author
Llorens Torres, Franc
dc.contributor.author
Fernández Irigoyen, Joaquín
dc.contributor.author
Santamaría, Enrique
dc.contributor.author
Ferrer, Isidro (Ferrer Abizanda)
dc.date.issued
2021-02-09T11:58:59Z
dc.date.issued
2021-02-09T11:58:59Z
dc.date.issued
2020-11-01
dc.date.issued
2021-02-09T11:58:59Z
dc.identifier
https://hdl.handle.net/2445/173799
dc.description.abstract
Abstract Sporadic amyotrophic lateral sclerosis (sALS) is a fatal progressive neurodegenerative disease affecting upper and lower motor neurons. Biomarkers are useful to facilitate the diagnosis and/or prognosis of patients and to reveal possible mechanistic clues about the disease. This study aimed to identify and validate selected putative biomarkers in the cerebrospinal fluid (CSF) of sALS patients at early disease stages compared with age-matched controls and with other neurodegenerative diseases including Alzheimer disease (AD), spinal muscular atrophy type III (SMA), frontotemporal dementia behavioral variant (FTD), and multiple sclerosis (MS). SWATH acquisition on liquid chromatography-tandem mass spectrometry (LC-MS/MS) for protein quantitation, and ELISA for validation, were used in CSF samples of sALS cases at early stages of the disease. Analysis of mRNA and protein expression was carried out in the anterior horn of the lumbar spinal cord in post-mortem tissue of sALS cases (terminal stage) and controls using RTq-PCR, and Western blotting, and immunohistochemistry, respectively. SWATH acquisition on liquid chromatography-tandem mass spectrometry (LC-MS/MS) revealed 51 differentially expressed proteins in the CSF in sALS. Receiver operating characteristic (ROC) curves showed CXCL12 to be the most valuable candidate biomarker. We validated the values of CXCL12 in CSF with ELISA in two different cohorts. Besides sALS, increased CXCL12 levels were found in MS but were not altered in AD, SMA, and FTD. Therefore, increased CXCL12 levels in the CSF can be useful in the diagnoses of MS and sALS in the context of the clinical settings. CXCL12 immunoreactivity was localized in motor neurons in control and sALS, and in a few glial cells in sALS at the terminal stage; CXCR4 was in a subset of oligodendroglial-like cells and axonal ballooning of motor neurons in sALS; and CXCR7 in motor neurons in control and sALS, and reactive astrocytes in the pyramidal tracts in terminal sALS. CXCL12/CXCR4/CXCR7 axis in the spinal cord probably plays a complex role in inflammation, oligodendroglial and astrocyte signaling, and neuronal and axonal preservation in sALS
dc.format
application/pdf
dc.format
application/pdf
dc.relation
Reproducció del document publicat a: https://doi.org/10.3390/ijms21228680
dc.relation
International Journal of Molecular Sciences, 2020, vol. 21, num. 8680
dc.relation
https://doi.org/10.3390/ijms21228680
dc.rights
cc-by (c) Andrés Benito, Pol et al., 2020
dc.rights
http://creativecommons.org/licenses/by/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Ciències Clíniques)
dc.subject
Esclerosi lateral amiotròfica
dc.subject
Marcadors bioquímics
dc.subject
Amyotrophic lateral sclerosis
dc.subject
Biochemical markers
dc.title
Increased C-X-C Motif Chemokine Ligand 12 Levels in Cerebrospinal Fluid as a Candidate Biomarker in Sporadic Amyotrophic Lateral Sclerosis
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion